Clover Bio Starts Construction of R&D Center in Zhangjiang Hi-Tech Park
publication date: Jan 6, 2022
Chengdu Clover Biopharma started construction of a Shanghai R&D Center to develop novel vaccines and biologic therapies. The facility, which will be built on 25,000 square meters of land, will contain a state-of-the-art preclinical research laboratory, manufacturing process development labs and a GMP pilot manufacturing plant. The facility will be located in Zhangjiang Biotech and Pharmaceutical Industrial Base in Zhangjiang Hi-Tech Park. Clover also announced the start of clinical trials of a booster shot of its COVID-19 vaccine following two original doses. More details....
Stock Symbol: (HK: 02197)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.